BioSpace News Archive

MaaT Pharma presented detailed results from the completed Phase 1b CIMON trial with MaaT033 at the Annual Society of Hematology Annual Meeting in New Orleans, U.S.

Graphite Bio, Inc. presented preclinical results supporting the use of a single-cell RNA sequencing method to assess gene correction outcomes in patients treated with nulabeglogene autogedtemcel, an investigational gene-edited therapy for sickle cell disease.

Regeneron Pharmaceuticals, Inc. announced positive new and updated data from a Phase 1 and pivotal Phase 2 trial evaluating investigational odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Boston Scientific Corporation and Acotec Scientific Holdings Limited announced that Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of Acotec, a Chinese medical technology company that offers solutions designed for a variety of interventional procedures.

Ajax Therapeutics, Inc. announced the presentation of preclinical data on the company’s next generation Type II JAK2 inhibitor, AJ1-10502, at a poster session held today at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans.

Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD117 and CD123 Shielded Cell & Immunotherapy Pairs program during this weekend’s American Society of Hematology meeting in New Orleans.

Ryvu Therapeutics announced new data demonstrating clinical and preclinical activity of its selective CDK8/19 inhibitor RVU120 and its selective PIM/FLT3 inhibitor SEL24 at the 64th American Society of Hematology Annual Meeting & Exposition, which is being held on December 10–13, 2022, in New Orleans, Louisiana.

Wugen, Inc. presented data on WU-NK-101, the company’s lead memory natural killer cell therapy product, at the 64th Annual Meeting of the American Society of Hematology taking place December 10 – 13, 2022 in New Orleans, Louisiana.

Kite, a Gilead Company, announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion for Yescarta® in adult patients with relapsed or refractory large B-cell lymphoma.

Coagulant Therapeutics Corporation announced data from pre-clinical studies on a novel llama-derived antibody library directed to the APC exosite.